Abstract: The present disclosure relates to new folate-conjugates comprising a 5-methyltetrahydrofolate, a radiometal chelator optionally coordinating a radiometal M, and an albumin binder linked through a hydrophobic linker, and further provides uses of such conjugates and/or pharmaceutical compositions thereof in diagnostic imaging, radionuclide therapy or theragnostic applications.

Abstract: The present invention relates to an LC medium comprising two or more polymerizable compounds, at least one of which contains a substituent comprising a tertiary OH group, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the PSA (polymer sustained alignment) or SA (self-aligning) mode, to an LC display of the PSA or SA mode comprising the LC medium, and to a process of manufacturing the LC display using the LC medium, especially an energy-saving LC display and energy-saving LC display production process.

Abstract: An optical component is described which contains a liquid crystal (LC) medium, operable in the infrared region of the electromagnetic spectrum. The LC medium, which can be used in the infrared (IR) region, can contain one or more compounds of the formulae I, II, and III in which the occurring groups and parameters have the meanings defined herein, and preferably contain one or more compounds of the formula RO in which the occurring groups and parameters have the meanings defined herein.

Abstract: The present invention relates to a liquid crystal (LC) medium comprising a compound of formula I and one or more compounds selected from the group of compounds of the formulae IIA, IIB, IIC and IID, as defined in claim 1, and to the use thereof for optical, electro-optical and electronic purposes, in particular in LC displays, especially in IPS, FFS, VA or PS-VA displays.

Abstract: Methods, compositions, and medical kits are useful for treating and preventing multiple sclerosis using 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one, or a pharmaceutically acceptable salt thereof, according to preferred dosing regimens.

Abstract: An atomic layer etching method using a ligand exchange reaction may include a substrate providing step of putting a substrate with a thin film formed thereon into a reaction chamber, a halogenated thin film forming step of forming a halogenated thin film on a surface of the thin film by infusing a halogenated gas into the reaction chamber, and an etching step of etching the halogenated thin film by infusing a ligand without a metal or metal precursor into the reaction chamber with the substrate with the halogenated thin film.

Abstract: The invention relates to substituted heterocycles of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

Abstract: A liquid crystal device for absorbing and/or scattering a controllable amount of traversing light comprises an active layer having a first viewport surface, a second viewport surface, and at least two side surfaces. The first and second viewport surfaces contact respective first and second planar electrodes. The first and second planar electrodes respectively comprise first and second supply areas for receiving a control voltage for controlling the active layer. A first supply contacting device electrically connects to the first supply area, and a second supply contacting device electrically connects to the second supply area. The supply areas and the supply contacting devices each associate to one or more side surfaces, arranged to extend along at least a part of their respective associated sides, wherein the first supply contacting device and the second supply contacting device associate to adjacent side surfaces.

Abstract: The present invention relates to compounds of formula (I), to processes for producing the compounds, and to electronic devices containing at least one compound of formula (I).

Abstract: A process for the production of flake-form, crystalline particles having an aurivillius structure, the use thereof as effect pigments or as substrates of effect pigments, furthermore, effect pigments which contain coated or uncoated flake-form, crystalline particles having an aurivillius structure as substrates, and the use thereof in various products.

Abstract: The invention relates to a liquid-crystalline medium, in particular based on a mixture of polar compounds, and to the use thereof for an active-matrix display, in particular based on the VA, SA-VA, IPS, PS-IPS, FFS, PS-FFS, UB-FFS or PS-UB-FFS effect.

Abstract: Compounds of formula I liquid crystal media containing these compounds, and high-frequency components containing these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, phased array antennas, and devices containing these components, and furthermore optical components containing these liquid-crystalline media, operable in the infrared region of the electromagnetic spectrum.

Abstract: To provide a method for manufacturing a cured film having high film density, high film hardness and high etching resistance. A method for manufacturing a cured film comprising (1) applying a composition (i) above a substrate; (2) forming a hydro-carbon-containing film from the composition (i); and (3) irradiating the hydrocarbon-containing film with plasma, electron beam and/or ion to form a cured film. Use of the cured film.

Abstract: A liquid crystal display (LCD) of the chiral polymer stabilized alignment (C-PSA) mode, a method of its production and its use as an energy-saving display.

Abstract: The present invention relates to methods for purifying adeno-associated virus particles by cation exchange mixed mode chromatography.

Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.

Abstract: A liquid-crystal (LC) medium containing one or more dyes and one or more polymerizable compounds, its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in colour LC displays of the PSA (polymer sustained alignment) or SA (self-aligning) mode containing a quantum dot colour filter (QDCF), an LC display of the PSA or SA mode containing the LC medium and containing a QDCF, and to a process of manufacturing the LC display.

Abstract: The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 antagonist, an ATR inhibitor and a platinating agent.

Abstract: The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.

Abstract: A silicon precursor compound according to Formula I as described herein is used to form a silicon-containing thin film having excellent quality. A preparation method therefor, and a silicon-containing thin film preparation method using the silicon precursor compound are also described.